Metabolomics and Chemical Library Screening for Antibacterial
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
(12) United States Patent (10) Patent No.: US 7,879,798 B1 Aufseeser (45) Date of Patent: Feb
US007879798B1 (12) United States Patent (10) Patent No.: US 7,879,798 B1 Aufseeser (45) Date of Patent: Feb. 1, 2011 (54) COMPOSITION FOR INDOLENT WOUND Mazzotta, M.Y. “Nutrition and Wound Healing.” J. Am. Podiatr. Med. HEALING AND METHODS OF USE Assoc. 84(9): 456-462, Sep. 1994. THEREFOR Niedermeier, S. "Tierexperimentelle Untersuchungen Zur Frage der Behandlung von Hornhautlasionen Animal experiment studies on the problem of treating corneal lesions.” Klin. Monatsbl. (75) Inventor: Leslie S. Aufseeser, Lakewood, NJ (US) Augenheilkd (Germany, West), 190 (1):28-9, Jan. 1987. Seifter, E. etal. “Impaired Wound Healing in Streptozotocin diabetes. (73) Assignee: Regenicel, Inc., Lakewood, NJ (US) Prevention by supplemental Vitamin A.” Ann. Surgery (US). 194(1): 42-50, Jul. 1981. (*) Notice: Subject to any disclaimer, the term of this Gilmore, O.J.A. etal. “Aetiology and prevention of wound infection patent is extended or adjusted under 35 in appendicetomy.” British Journal of Surgery, 61:281-287. Mar. U.S.C. 154(b) by 594 days. 1974. Lowenfels, Albert B. “Viewpoints: Wound Healing With No Oint (21) Appl. No.: 11/895,474 ment, Non-antibiotic Ointment, or Antibiotic Ointment”. Medscape General Surgery. 8(2), 2006. (22) Filed: Aug. 24, 2007 United States Food and Drug Administration. “First Aid Antibiotic Drug Products”. Code of Federal Regulations, Title 21, vol. 5, Chap (51) Int. Cl. ter I, Part 333, Subpart B, pp. 222-225, Apr. 1, 2006. A6 IK 38/12 (2006.01) Akpek, EK et al. "A randomized trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis.” (52) U.S. -
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
01012100 Pure-Bred Horses 0 0 0 0 0 01012900 Lives Horses, Except
AR BR UY Mercosu PY applied NCM Description applied applied applied r Final Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 Other bovine animals for breeding,pregnant or 01022911 lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 Other buffalo for breeding, ex. pure-bred or 01023911 pregnant 2 2 2 2 0 Other buffalo for breeding, except pure-bred 01023919 breeding 2 2 2 2 4 01023990 Other buffalos 2 2 2 2 0 01029000 Other live animals of bovine species 0 0 0 0 0 01031000 Pure-bred breedig swines 0 0 0 0 0 01039100 Other live swine, weighing less than 50 kg 2 2 2 2 0 01039200 Other live swine, weighing 50 kg or more 2 2 2 2 0 01041011 Pure-bred breeding, pregnant or lactating, sheep 0 0 0 0 0 01041019 Other pure-bred breeding sheep 0 0 0 0 0 01041090 Others live sheep 2 2 2 2 0 01042010 Pure-bred breeding goats 0 0 0 0 0 01042090 Other live goats 2 2 2 2 0 Fowls spec.gallus domestic.w<=185g pure-bred 01051110 breeding 0 0 0 0 0 Oth.live fowls spec.gall.domest.weig.not more than 01051190 185g 2 2 2 2 0 01051200 Live turkeys, weighing not more than 185g 2 2 -
Topical and Systemic Antifungal Therapy for Chronic Rhinosinusitis (Protocol)
CORE Metadata, citation and similar papers at core.ac.uk Provided by University of East Anglia digital repository Cochrane Database of Systematic Reviews Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Head K, Sacks PL, Chong LY, Hopkins C, Philpott C Head K, Sacks PL, Chong LY, Hopkins C, Philpott C. Topical and systemic antifungal therapy for chronic rhinosinusitis. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD012453. DOI: 10.1002/14651858.CD012453. www.cochranelibrary.com Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 3 METHODS ...................................... 3 ACKNOWLEDGEMENTS . 8 REFERENCES ..................................... 9 APPENDICES ..................................... 10 CONTRIBUTIONSOFAUTHORS . 25 DECLARATIONSOFINTEREST . 26 SOURCESOFSUPPORT . 26 NOTES........................................ 26 Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) i Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Protocol] Topical and systemic antifungal therapy for chronic rhinosinusitis Karen Head1, Peta-Lee Sacks2, Lee Yee Chong1, Claire Hopkins3, Carl Philpott4 1UK Cochrane Centre, -
Control of Intestinal Protozoa in Dogs and Cats
Control of Intestinal Protozoa 6 in Dogs and Cats ESCCAP Guideline 06 Second Edition – February 2018 1 ESCCAP Malvern Hills Science Park, Geraldine Road, Malvern, Worcestershire, WR14 3SZ, United Kingdom First Edition Published by ESCCAP in August 2011 Second Edition Published in February 2018 © ESCCAP 2018 All rights reserved This publication is made available subject to the condition that any redistribution or reproduction of part or all of the contents in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise is with the prior written permission of ESCCAP. This publication may only be distributed in the covers in which it is first published unless with the prior written permission of ESCCAP. A catalogue record for this publication is available from the British Library. ISBN: 978-1-907259-53-1 2 TABLE OF CONTENTS INTRODUCTION 4 1: CONSIDERATION OF PET HEALTH AND LIFESTYLE FACTORS 5 2: LIFELONG CONTROL OF MAJOR INTESTINAL PROTOZOA 6 2.1 Giardia duodenalis 6 2.2 Feline Tritrichomonas foetus (syn. T. blagburni) 8 2.3 Cystoisospora (syn. Isospora) spp. 9 2.4 Cryptosporidium spp. 11 2.5 Toxoplasma gondii 12 2.6 Neospora caninum 14 2.7 Hammondia spp. 16 2.8 Sarcocystis spp. 17 3: ENVIRONMENTAL CONTROL OF PARASITE TRANSMISSION 18 4: OWNER CONSIDERATIONS IN PREVENTING ZOONOTIC DISEASES 19 5: STAFF, PET OWNER AND COMMUNITY EDUCATION 19 APPENDIX 1 – BACKGROUND 20 APPENDIX 2 – GLOSSARY 21 FIGURES Figure 1: Toxoplasma gondii life cycle 12 Figure 2: Neospora caninum life cycle 14 TABLES Table 1: Characteristics of apicomplexan oocysts found in the faeces of dogs and cats 10 Control of Intestinal Protozoa 6 in Dogs and Cats ESCCAP Guideline 06 Second Edition – February 2018 3 INTRODUCTION A wide range of intestinal protozoa commonly infect dogs and cats throughout Europe; with a few exceptions there seem to be no limitations in geographical distribution. -
Fluoroquinolones in Children: a Review of Current Literature and Directions for Future Research
Academic Year 2015 - 2016 Fluoroquinolones in children: a review of current literature and directions for future research Laurens GOEMÉ Promotor: Prof. Dr. Johan Vande Walle Co-promotor: Dr. Kevin Meesters, Dr. Pauline De Bruyne Dissertation presented in the 2nd Master year in the programme of Master of Medicine in Medicine 1 Deze pagina is niet beschikbaar omdat ze persoonsgegevens bevat. Universiteitsbibliotheek Gent, 2021. This page is not available because it contains personal information. Ghent Universit , Librar , 2021. Table of contents Title page Permission for loan Introduction Page 4-6 Methodology Page 6-7 Results Page 7-20 1. Evaluation of found articles Page 7-12 2. Fluoroquinolone characteristics in children Page 12-20 Discussion Page 20-23 Conclusion Page 23-24 Future perspectives Page 24-25 References Page 26-27 3 1. Introduction Fluoroquinolones (FQ) are a class of antibiotics, derived from modification of quinolones, that are highly active against both Gram-positive and Gram-negative bacteria. In 1964,naladixic acid was approved by the US Food and Drug Administration (FDA) as first quinolone (1). Chemical modifications of naladixic acid resulted in the first generation of FQ. The antimicrobial spectrum of FQ is broader when compared to quinolones and the tissue penetration of FQ is significantly deeper (1). The main FQ agents are summed up in table 1. FQ owe its antimicrobial effect to inhibition of the enzymes bacterial gyrase and topoisomerase IV which have essential and distinct roles in DNA replication. The antimicrobial spectrum of FQ include Enterobacteriacae, Haemophilus spp., Moraxella catarrhalis, Neiserria spp. and Pseudomonas aeruginosa (1). And FQ usually have a weak activity against methicillin-resistant Staphylococcus aureus (MRSA). -
From Sugar Based Bio Renewable Resources to New Chemical Building Blocks and Bioactive Molecules
Raquel Alexandra Germano Nunes Licenciatura em Química Aplicada From sugar based bio renewable resources to new chemical building blocks and bioactive molecules Dissertação para obtenção do Grau de Mestre em Química Bioorgânica Orientador: Prof. Doutor Carlos Alberto Mateus Afonso, FF-UL Co-orientador: Rafael Filipe Teixeira Arbuéz Gomes, MSc, FF-UL Presidente: Prof. Doutora Paula Cristina de Sério Branco, FCT-UNL Arguente: Prof. Doutora Luísa Maria da Silva Pinto Ferreira, FCT-UNL Vogal: Prof. Doutor Carlos Alberto Mateus Afonso, FF-UL Março 2017 LOMBADA Raquel Nunes Raquel From sugar based bio renewable resources to new chemical building blocks and bioactive molecules bioactive and blocks chemical new building to resources renewable bio based sugar From 2017 Raquel Alexandra Germano Nunes Licenciatura em Química Aplicada From sugar based bio renewable resources to new chemical building blocks and bioactive molecules Dissertação para obtenção do Grau de Mestre em Química Bioorgânica Orientador: Prof. Doutor Carlos Alberto Mateus Afonso, FF-UL Co-orientador: Rafael Filipe Teixeira Arbuéz Gomes, MSc, FF-UL Presidente: Prof. Doutora Paula Cristina de Sério Branco, FCT-UNL Arguente: Prof. Doutora Luísa Maria da Silva Pinto Ferreira, FCT-UNL Vogal: Prof. Doutor Carlos Alberto Mateus Afonso, FF-UL Março 2017 From sugar based bio renewable resources to new chemical building blocks and bioactive molecules Copyright © Raquel Alexandra Germano Nunes, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa. A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, perpétuo e sem limites geográficos, de arquivar e publicar esta dissertação através de exemplares impressos reproduzidos em papel ou de forma digital, ou por outro qualquer meio conhecido ou que venha a ser inventado e de divulgar através de repositórios científicos e de admitir a sua cópia e distribuição com objectivos educacionais ou de investigação, não comerciais, desde que seja dado crédito ao autor e editor. -
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine -
Download Product Insert (PDF)
PRODUCT INFORMATION Isoconazole (nitrate) Item No. 30100 CAS Registry No.: 24168-96-5 Cl Formal Name: 1-[2-(2,4-dichlorophenyl)-2-[(2,6- dichlorophenyl)methoxy]ethyl]-1H- imidazole, mononitrate Synonyms: Adestan G 100, R 15454 Cl Cl MF: C18H14Cl4N2O • HNO3 FW: 479.1 N N Purity: ≥98% O Supplied as: A solid Storage: -20°C • HNO3 Cl Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Isoconazole (nitrate) is supplied as a solid. A stock solution may be made by dissolving the isoconazole (nitrate) in the solvent of choice, which should be purged with an inert gas. Isoconazole (nitrate) is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of isoconazole (nitrate) in these solvents is approximately 10 mg/ml. Isoconazole (nitrate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, isoconazole (nitrate) should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Isoconazole (nitrate) has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Isoconazole is an imidazole with antimicrobial activity.1 It is active against clinical isolates of Candida species, including C. albicans, C. parapsilosis, C. tropicalis, C. krusei, and C. guilliermondii with MIC values ranging from 0.12 to 2 μg/ml. It is also active against the fungi T. mentagrophytes and T. rubrum when used at a concentration of 0.1 µg/ml and the bacteria C. -
Antibiotic Discovery
ANTIBIOTIC DISCOVERY RESISTANCE PROFILING OF MICROBIAL GENOMES TO REVEAL NOVEL ANTIBIOTIC NATURAL PRODUCTS By CHELSEA WALKER, H. BSc. A Thesis Submitted to the School of Graduate Studies in Partial Fulfilment of the Requirements for the Degree Master of Science McMaster University © Copyright by Chelsea Walker, May 2017 McMaster University MASTER OF SCIENCE (2017) Hamilton, Ontario (Biochemistry and Biomedical Sciences) TITLE: Resistance Profiling of Microbial Genomes to Reveal Novel Antibiotic Natural Products. AUTHOR: Chelsea Walker, H. BSc. (McMaster University) SUPERVISOR: Dr. Nathan A. Magarvey. COMMITTEE MEMBERS: Dr. Eric Brown and Dr. Michael G. Surette. NUMBER OF PAGES: xvii, 168 ii Lay Abstract It would be hard to imagine a world where we could no longer use the antibiotics we are routinely being prescribed for common bacterial infections. Currently, we are in an era where this thought could become a reality. Although we have been able to discover antibiotics in the past from soil dwelling microbes, this approach to discovery is being constantly challenged. At the same time, the bacteria are getting smarter in their ways to evade antibiotics, in the form of resistance, or self-protection mechanisms. As such is it essential to devise methods which can predict the potential for resistance to the antibiotics we use early in the discovery and isolation process. By using what we have learned in the past about how bacteria protect themselves for antibiotics, we can to stay one step ahead of them as we continue to search for new sources of antibiotics from bacteria. iii Abstract Microbial natural products have been an invaluable resource for providing clinically relevant therapeutics for almost a century, including most of the commonly used antibiotics that are still in medical use today. -
Kentucky Horse Racing Commission Withdrawal Guidelines Thoroughbred; Standardbred; Quarter Horse, Appaloosa, and Arabian KHRC 8-020-2 (11/2018)
Kentucky Horse Racing Commission Withdrawal Guidelines Thoroughbred; Standardbred; Quarter Horse, Appaloosa, and Arabian KHRC 8-020-2 (11/2018) General Notice Unless otherwise specified in these withdrawal guidelines or the applicable regulations and statutes, the following withdrawal guidelines are voluntary and advisory. The guidelines are recommendations based on current scientific knowledge that may change over time. A licensee may present evidence of full compliance with these guidelines to the Kentucky Horse Racing Commission (the “Commission” or “KHRC”) and the stewards as a mitigating factor to be used in determining violations and penalties. These withdrawal interval guidelines assume that administration of medications will be performed at doses that are not greater than the manufacturer’s maximum recommended dosage. Medications administered at dosages above manufacturer’s recommendations, in compounded formulations and/or in combination with other medications and/or administration inside the withdrawal interval may result in test sample concentrations above threshold concentrations that could lead to positive test results and the imposition of penalties. The time of administration of an orally administered substance, for the purposes of withdrawal interval, shall be considered to be the time of complete ingestion of the medication by the horse via eating or drinking. Brand names of medications, where applicable, are listed in parentheses or brackets following the generic name of a drug. In addition to the requirements contained in KRS Chapter 13A, the KHRC shall give notice of an amendment or addition to these withdrawal guidelines by posting the change on the KHRC website and at all Kentucky racetracks at least two weeks before the amendment or addition takes legal effect. -
Pharmacokinetics of Veterinary Drugs in Laying Hens and Residues in Eggs: a Review of the Literature
J. vet. Pharmacol. Therap. doi: 10.1111/j.1365-2885.2011.01287.x REVIEW ARTICLE Pharmacokinetics of veterinary drugs in laying hens and residues in eggs: a review of the literature V. GOETTING Goetting, V., Lee, K. A., Tell, L. A. Pharmacokinetics of veterinary drugs in K. A. LEE & laying hens and residues in eggs: a review of the literature. J. vet. Pharmacol. Therap. doi: 10.1111/j.1365-2885.2011.01287.x. L. A. TELL Department of Medicine and Epidemiology, Poultry treated with pharmaceutical products can produce eggs contaminated School of Veterinary Medicine, University with drug residues. Such residues could pose a risk to consumer health. The of California, Davis, CA, USA following is a review of the information available in the literature regarding drug pharmacokinetics in laying hens, and the deposition of drugs into eggs of poultry species, primarily chickens. The available data suggest that, when administered to laying hens, a wide variety of drugs leave detectable residues in eggs laid days to weeks after the cessation of treatment. (Paper received 10 September 2010; accepted for publication 12 February 2011) Lisa A. Tell, Department of Medicine and Epidemiology, University of California at Davis, One Shields Avenue, Davis, CA 95616, USA. E-mail: latell@ucdavis INTRODUCTION from extra-label drug use, then the exposed animal(s) should not enter the food chain unless permission is granted from the proper In poultry, antibiotics and antiparasitics are used extensively for authorities. In both the US and EU, other drugs, including disease prevention and treatment. In the United States, antibiotics chloramphenicol, the nitroimidazoles, and nitrofurans, are are also used for growth promotion, although this type of use has completely prohibited from use in food animals (Davis et al., been prohibited in the European Union since 2006 (Donoghue, 2009; EMEA, 2009).